Screen design: generation of mammary cancer cell lines LB‐mHR1 (HR1) from
PIK3CA
H1047R mutant transgenic animals and transfection with the
piggyBac (PB) system (HR1 Ctrl and HR1. PB cells) (Ivics
et al,
2009). PB transposon (ATP1‐Puro) and transposase (pFS250. PBase) plasmid design. PB‐3’/5’,
piggyBac inverted terminal repeats; CβASA, Carp β‐actin splice acceptor; En2SA, Engrailed‐2 exon‐2 splice acceptor; SD, Foxf2 exon‐1 splice donor; pA, bidirectional SV40 polyadenylation signal; PGK, mouse phosphoglycerate kinase 1 promoter; Puro, puromycin resistance; CAG, cytomegalovirus enhancer and chicken beta‐actin promoter; Tet‐ON, tetracycline‐responsive element‐tight promoter; PBase, PB transposase; UbC, Ubiquitin C promoter; rTTA3, reverse tetracycline transactivator 3; IRES, internal ribosomal entry site; Neo, Neomycin/G418 selection marker. The cell pools were treated with doxycycline (1 μg/ml) for 96 h
in vitro.